IL175424A0 - 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) - Google Patents

4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Info

Publication number
IL175424A0
IL175424A0 IL175424A IL17542406A IL175424A0 IL 175424 A0 IL175424 A0 IL 175424A0 IL 175424 A IL175424 A IL 175424A IL 17542406 A IL17542406 A IL 17542406A IL 175424 A0 IL175424 A0 IL 175424A0
Authority
IL
Israel
Prior art keywords
quinolinecarbonitriles
cml
anilino
treatment
myelogenous leukemia
Prior art date
Application number
IL175424A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL175424(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL175424A0 publication Critical patent/IL175424A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL175424A 2003-11-06 2006-05-04 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) IL175424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
PCT/US2004/036722 WO2005046693A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Publications (1)

Publication Number Publication Date
IL175424A0 true IL175424A0 (en) 2008-04-13

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175424A IL175424A0 (en) 2003-11-06 2006-05-04 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Country Status (18)

Country Link
US (2) US7417148B2 (enExample)
EP (1) EP1680119A1 (enExample)
JP (1) JP2007533655A (enExample)
KR (1) KR20060118461A (enExample)
CN (1) CN1874776A (enExample)
AU (1) AU2004289243B2 (enExample)
BR (1) BRPI0416289A (enExample)
CA (1) CA2543163A1 (enExample)
CO (1) CO5690608A2 (enExample)
CR (1) CR8350A (enExample)
EC (1) ECSP066548A (enExample)
IL (1) IL175424A0 (enExample)
MX (1) MXPA06004744A (enExample)
NO (1) NO20062255L (enExample)
RU (1) RU2006113691A (enExample)
SG (1) SG146681A1 (enExample)
WO (1) WO2005046693A1 (enExample)
ZA (1) ZA200603596B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
MX2007016230A (es) * 2005-06-17 2008-03-06 Univ Texas Inhibicion de lesiones osteoliticas mediante inhibidores de quinasa src.
AU2006262591A1 (en) * 2005-06-24 2007-01-04 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
ES2881391T3 (es) 2007-06-01 2021-11-29 Wyeth Llc Tratamiento de leucemia mielógena crónica resistente a imatinib que tiene la mutación 1457T>C en el gen BcrAbl usando el compuesto bosutinib
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
IN2014CH00840A (enExample) 2014-02-20 2015-09-18 Apotex Inc
CN113181362B (zh) 2015-01-13 2023-06-13 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
KR20060118461A (ko) 2006-11-23
MXPA06004744A (es) 2006-07-05
AU2004289243B2 (en) 2010-07-22
EP1680119A1 (en) 2006-07-19
ZA200603596B (en) 2009-12-30
SG146681A1 (en) 2008-10-30
CN1874776A (zh) 2006-12-06
US20100029677A1 (en) 2010-02-04
AU2004289243A1 (en) 2005-05-26
ECSP066548A (es) 2006-10-17
RU2006113691A (ru) 2007-12-20
US7417148B2 (en) 2008-08-26
BRPI0416289A (pt) 2007-01-23
US20050101780A1 (en) 2005-05-12
CA2543163A1 (en) 2005-05-26
CO5690608A2 (es) 2006-10-31
US7919625B2 (en) 2011-04-05
JP2007533655A (ja) 2007-11-22
CR8350A (es) 2006-10-06
WO2005046693A1 (en) 2005-05-26
NO20062255L (no) 2006-08-01

Similar Documents

Publication Publication Date Title
EP1689485A4 (en) CARDIOELECTROMAGNETIC TREATMENT
EP1638508A4 (en) SHUNT FOR GLUCKOM TREATMENT
EP1749827A4 (en) ANTITUMOR AGENTS
IL164896A0 (en) Immunoconjugates for the treatment of tumours
GB0326486D0 (en) Combination treatment
IL175424A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
GB0312407D0 (en) Treatment
EP1536719A4 (en) TABLE
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
AU154131S (en) Table
GB2405789B (en) Patient table
AU154258S (en) Game table
AU154608S (en) Game table
AU2003291245A8 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
AP2956A (en) Parasiticidal composition
GB2404587B (en) Parasiticidal composition
PT1590046T (pt) Composição para o tratamento de hiv ou sida
IL175689A0 (en) Enoxaparin for the treatment of cancer
HK1086761A (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
GB0313630D0 (en) Compositions for the enhanced treatment of depression
GB0316502D0 (en) The structure of exotic panties
AU157684S (en) Router table
GB0327493D0 (en) Treatment medicament
AU157347S (en) Treatment table
GB2398266B (en) Table